Document:

<PAGE>

                                                                 Exhibit 10.39.1

                                                                       Execution

                                    AGREEMENT

         This Agreement (this "Agreement"), dated as of February 28, 2003, is
entered into among DELTAGEN, INC., a Delaware corporation with a place of
business at 740 Bay Road, Redwood City, CA 94063 ("Deltagen"), and BRISTOL-MYERS
SQUIBB COMPANY, a Delaware corporation with a place of business at Route 206 and
Province Line Road, Princeton, NJ 08543 ("BMS").

         WHEREAS, BMS would like to obtain a DeltaOne(TM) license from Deltagen;

         WHEREAS, Deltagen would like BMS' affiliate, Bristol-Myers Squibb
Pharma Company ("BMS Pharma", f/k/a DuPont Pharmaceuticals Company), to assume
that certain Lease dated February 23, 1999 (the "Lease") between Deltagen's
wholly owned subsidiary, Deltagen Research Laboratories, LLC ("DRL", f/k/a
CombiChem, Inc.), and LMC Executive Investment Company, LLC, as successor to LMC
Shoreham Investment Company, LLC and Convoy Court Investment Company, LLC, as
tenants in common (the "Landlord");

         WHEREAS, concurrently with the execution of this Agreement, BMS and
Deltagen have caused BMS Pharma and DRL, respectively, to execute and deliver a
Lease Assignment and Assumption Agreement in the form annexed hereto as Exhibit
A (the "Assignment") pursuant to which DRL has assigned the Lease to BMS Pharma
and BMS Pharma has assumed the obligations of the tenant under the Lease,
subject in each case to receipt of Landlord's written consent thereto; and

         WHEREAS, if Deltagen successfully raises additional debt or equity
financing as hereinafter provided, BMS and Deltagen have agreed that effective
as of the date of the consummation of such equity transaction:

               (a) BMS shall release Deltagen from its obligations relating to
the Lease under (i) that certain Purchase Agreement dated as of February 8,
2002, as amended by that certain Amendment dated as of February 14, 2002
(collectively, the "Purchase Agreement") between Deltagen and BMS and (ii) the
Related Instruments (as such term is defined in the Purchase Agreement), in each
case except for obligations relating to the period between February 16, 2002 and
March 1, 2003 (the "Excluded Period") and (b) BMS shall terminate that certain
Guaranty dated February 16, 2002 (the "Guaranty") by Deltagen in favor of BMS
and the other Beneficiaries (as such term is defined in the Guaranty) with
respect to all obligations of Deltagen under the Guaranty except for obligations
relating to the Excluded Period. In addition, BMS shall release Deltagen from
any obligation to pay the $296,422.61 in rent and other charges due under the
Lease as of February 1, 2003 and any late charges or fees relating thereto not
paid by DRL (collectively, the "Outstanding Amount").

               (b) Deltagen shall grant BMS a credit to be applied against any
fees due under the DeltaOneTM Agreement (defined below).

               (c) BMS Pharma shall indemnify DRL and Deltagen against and hold
DRL and Deltagen harmless from any and all cost, liability, loss, damage or
expense,

<PAGE>

                                                                               2

including, without limitation, attorneys' fees, (i) arising out of the tenant's
obligations under the Lease arising or accruing from and after March 1, 2003 and
(ii) any obligation to pay the Outstanding Amount.

         NOW, THEREFORE, intending to be legally bound, the parties agree as
follows:

         1. Concurrently with the execution of this Agreement, Deltagen and BMS
have entered into the DeltaOne(TM) Agreement attached hereto as Exhibit B (the
"DeltaOne(TM) Agreement").

         2. Deltagen (a) represents and warrants to BMS that (i) the Lease has
not been amended or modified since the closing under the Purchase Agreement and
(ii) to the best knowledge of Deltagen and DRL, except for (x) the failure of
DRL to pay the Outstanding Amount and (y) the claim made by the landlord under
the Lease which is described in Section 4.13 of the Disclosure Schedule to the
Purchase Agreement, there are currently no defaults of the either the tenant or
the landlord under the Lease and no event which, with notice or lapse of time or
both, would constitute a default of the tenant or the landlord under the Lease,
(b) agrees that, unless Sections 3(a), 3(b), 3(c), 3(d) and 3(e) of this
Agreement become effective, the Assignment does not (i) release Deltagen from,
or operate as a waiver by BMS of any of, Deltagen's obligations and agreements
under the Purchase Agreement, the Guaranty or any other Related Instrument (as
such term is defined in the Purchase Agreement), whether such obligations or
agreements relate to the Lease or other matters, or (ii) preclude any exercise
of any right or power by BMS under the Purchase Agreement, the Guaranty or any
other Related Instrument and (c) consents to any amendment or modification of
the Lease entered into by BMS Pharma or its successors and assigns after the
date hereof in order to facilitate the subleasing of the premises demised by the
Lease or the further assignment of the Lease and agrees that, except as
expressly provided in this Agreement, no such amendment or modification shall
(i) release Deltagen from, or operate as a waiver by BMS of, any of Deltagen's
obligations and agreements under the Purchase Agreement, the Guaranty or any
other Related Instrument, whether such obligations or agreements relate to the
Lease or other matters, or (ii) preclude any exercise of any right or power by
BMS under the Purchase Agreement, the Guaranty or any other Related Instrument,
provided that notwithstanding anything to the contrary in this Agreement, the
Purchase Agreement, the Guaranty or in any Related Instrument, in no event shall
Deltagen be responsible or liable to BMS for any increase in the obligations of
the tenant under the Lease resulting from any such amendment, modification or
assignment. Notwithstanding the foregoing, BMS agrees that BMS shall not assert
a claim or take any legal action against Deltagen under the Purchase Agreement,
the Guaranty or any Related Instrument, or otherwise, in each case with respect
to the Lease, prior to March 31, 2003 (the "Outside Date"), provided that if
Sections 3(a), 3(b), 3(c), 3(d) and 3(e) of this Agreement do not become
effective, this limitation shall not affect the rights of BMS to assert such
claims or to take such actions after the Outside Date with regard to the period
prior to the Outside Date. If Sections 3(a), 3(b), 3(c), 3(d) and 3(e) of this
Agreement do become effective, BMS's rights to make such claims will be limited
only by Sections 3(a), 3(b), 3(c) and 3(d) of this Agreement.

<PAGE>

                                                                               3

         3. Notwithstanding anything in this Agreement to the contrary, the
effectiveness of the provisions of Sections 3(a), 3(b), 3(c), 3(d) and 3(e) of
this Agreement are expressly conditioned on Deltagen's consummation, on or prior
to the Outside Date, of one or more debt or equity investments in Deltagen (by
persons other than subsidiaries of, or other entities controlled by, Deltagen)
which provide Deltagen with net cash proceeds in an aggregate amount of not less
than $2,000,000 in immediately available funds. Deltagen shall provide BMS with
written evidence of both (i) the consummation of such equity investments and
(ii) the date of such consummation which, in each case, is reasonably
satisfactory to BMS. If it is on or prior to the Outside Date, the date upon
which such equity investments are consummated shall be the date upon which
Sections 3(a), 3(b), 3(c), 3(d) and 3(e) of this Agreement shall automatically
become effective.

         (a) BMS, for itself and for the other Beneficiaries, (i) hereby agrees
that the Guaranty shall be terminated and no longer in effect but only with
respect to (x) the obligation to pay the Outstanding Amount and (y) all
obligations of Deltagen under the Guaranty except for obligations relating to
the Excluded Period and (ii) hereby forever and irrevocably releases, discharges
and acquits Deltagen and its affiliates, partners, officers, directors, agents,
trustees, beneficiaries, and employees of and from any and all claims, acts,
damages, liabilities, rights of action and causes of action which BMS or the
other Beneficiaries may have against Deltagen under the Guaranty which relate to
or arise from (A) periods other than the Excluded Period and (B) the obligation
to pay the Outstanding Amount.

         (b) BMS hereby forever and irrevocably releases, discharges and acquits
Deltagen and its affiliates, partners, officers, directors, agents, trustees,
beneficiaries, and employees of and from all of Deltagen's obligations and
agreements arising from or relating to (i) the Lease under the Purchase
Agreement and the Related Instruments relating to or arising during periods
other than the Excluded Period and (ii) the obligation to pay the Outstanding
Amount.

         (c) Except for the matters expressly released above, the foregoing
releases shall not (i) apply to Deltagen's remaining obligations and agreements
under the Purchase Agreement or any Related Instrument, all of which Deltagen
hereby ratifies and confirms, (ii) operate as a waiver by BMS of any such
remaining obligations and agreements of Deltagen under the Purchase Agreement or
any Related Instrument or (iii) preclude any exercise of any right or power by
BMS in respect of such remaining obligations and agreements under the Purchase
Agreement or any Related Instrument.

         (d) BMS Pharma hereby indemnifies DRL and Deltagen against and holds
DRL and Deltagen harmless from any and all cost, liability, loss, damage or
expense, including without limitation, attorneys' fees, arising out of the
tenant's obligations under the Lease relating to or arising from (i) the period
from and after March 1, 2003 and (ii) the obligation to pay the Outstanding
Amount.

         (e) Deltagen hereby grants BMS a credit of Five Million Dollars
($5,000,000.00) (the "Credit"), which Credit may only be applied against fees
due at any time and from

<PAGE>

                                                                               4

time to time under the DeltaOne(TM) Agreement during the term of the
DeltaOne(TM) Agreement. The Credit, or any portion thereof, shall not be
transferred or assigned (whether voluntarily, by operation of law or otherwise)
by BMS to any other party without the prior written consent of Deltagen, which
consent shall be granted or withheld in Deltagen's sole and absolute discretion.
Any such transfer or assignment of the Credit, or any portion thereof, without
Deltagen's prior written consent shall be null and void. Notwithstanding
anything else contained in this Agreement, Deltagen's consent shall not be
required for the transfer or assignment of all or any portion of the Credit to
one or more Affiliates (as such term is defined in the Purchase Agreement) of
BMS. The parties agree that the Credit represents fair and adequate
consideration to BMS for entering into this Agreement.

         4. Notwithstanding anything else contained in this Agreement, BMS and
Deltagen agree to cooperate to require the applicable insurance carrier to pay
and/or defend any claim covered by liability insurance that was carried by DRL,
f/k/a BMSPRL, L.L.C., a Delaware limited liability company, successor by
conversion pursuant to Section 266 of the Delaware General Corporation Law to
Bristol-Myers Squibb Pharma Research Labs, Inc., a Delaware corporation, f/k/a
Dupont Pharmaceuticals Research Laboratories, Inc., a Delaware corporation,
f/k/a CombiChem, Inc., including any claim for indemnification made by the
Landlord relating to such a claim. This Section 4 is not intended to alter the
ultimate responsibility for any such claim pursuant to this Agreement, and the
party ultimately responsible for any such claim under this Agreement shall bear
any out-of-pocket costs associated with requiring any such insurance carrier to
pay such a claim. Insurance carriers are not intended to be subrogated to the
rights of any party to this Agreement under this Agreement.

         5. Deltagen and BMS agree that this Agreement will not be effective
unless and until (a) BMS Pharma and DRL have executed and delivered the
Assignment, (b) BMS and Deltagen have executed and delivered the DeltaOne(TM)
Agreement and (c) the Landlord has executed and delivered the Landlord Consent
in substantially the form annexed to the Assignment.

         6. Except as otherwise expressly provided under this Agreement, neither
this Agreement nor any right or obligation hereunder may be assigned or
otherwise transferred (whether voluntarily, by operation of law or otherwise),
without the prior express written consent of the other party; provided, however,
that without such consent, (a) a party may assign this Agreement and its rights
and obligations hereunder in connection with the transfer or sale of all or
substantially all of its business, or in the event of its merger, consolidation,
change in control or similar transaction, and (b) a party may assign this
Agreement and its rights and obligations hereunder, in whole or part, to an
affiliate. Any permitted successor or assignee shall assume all obligations of
its transferor or assignor under this Agreement. Any purported assignment or
transfer in violation of this Section 6 shall be void.

         7. This Agreement shall be governed by and construed in accordance with
the laws of the State of New York, without regard to the conflicts of law
principles thereof.

<PAGE>

                                                                               5

         8.  This Agreement, including all Exhibits hereto, contains the entire
understanding of the parties with respect to the subject matter hereof. All
express or implied representations, agreements and understandings, either oral
or written, heretofore made are expressly superseded by this Agreement. This
Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by all of the parties hereto. In the event that there
is a conflict between the terms and conditions set out in the body of this
Agreement and those set forth on any Exhibits hereto, the terms and conditions
set forth in the body of this Agreement shall control.

         9.  Each party hereby acknowledges that the parties shall be
independent contractors and that the relationship between the parties shall not
constitute a partnership, joint venture or agency. Neither party shall have the
authority to make any statements, representations or commitments of any kind, or
to take any action, which shall be binding on the other party, without the prior
consent of the other party to do so.

         10. If any provision of this Agreement, or the application thereof to
any person, entity, place or circumstance, shall be held by a court of competent
jurisdiction to be invalid, unenforceable or void, the remainder of this
Agreement and such provisions as applied to other persons, entities, places and
circumstances shall remain in full force and effect only if, after excluding the
portion deemed to be unenforceable, the remaining terms shall provide for the
consummation of the transactions contemplated hereby in substantially the same
manner as originally set forth herein. In such event, the parties shall
negotiate, in good faith, a substitute, valid and enforceable provision or
agreement that most nearly effects the parties' intent in entering into this
Agreement.

         11. Each of BMS and Deltagen represents and warrants to the other that
its execution and delivery of this Agreement has been duly authorized by all
requisite corporate action and that this Agreement constitutes a legal, valid
and binding obligation of BMS and Deltagen, respectively, enforceable in
accordance with its terms.

         12. This Agreement shall be binding upon the parties when executed and
delivered by facsimile transmission or by delivery of original executed
counterparts, whether executed by the parties on the same or on separate
counterparts, and each fully executed counterpart and/or each complete set of
executed counterparts shall be deemed an original, but all of which together
shall constitute one and the same instrument.

         13. The parties agree that no public release or announcement concerning
the transactions contemplated hereby (including, without limitation, execution
of the DeltaOne(TM) Agreement) shall be issued by either party without the
consent of the other party (which consent shall not be unreasonably withheld),
except as such release may be required by applicable laws or the rules or
regulations of any United States or foreign securities exchange, in which case
the party required to make the release or announcement shall allow the other
party reasonable time to comment on such release or announcement in advance of
such issuance; provided, however, that each of the parties may make internal
announcements to their respective employees that are consistent with the
parties' prior public disclosures regarding the transactions contemplated
hereby.

<PAGE>

                                                                               6

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first set forth above.

DELTAGEN, INC.

By:_____________________________
Name:___________________________
Title:__________________________

BRISTOL-MYERS SQUIBB COMPANY

By:_____________________________
Name:___________________________
Title:__________________________

BMS Pharma executes this Agreement below for the sole purpose of accepting and
agreeing to its obligation to indemnify DRL as provided in Section 3(d) hereof
upon satisfaction of the condition set forth in Section 3.

BRISTOL-MYERS SQUIBB PHARMA COMPANY

By:_____________________________
Name:___________________________
Title:__________________________<PAGE>

                                                                 Exhibit 10.39.2

                                                                       Execution

                    LEASE ASSIGNMENT AND ASSUMPTION AGREEMENT
                              WITH LANDLORD CONSENT

RECORDING REQUESTED BY AND              )
WHEN RECORDED, RETURN TO:               )

Bristol-Myers Squibb Pharma Company     )
Post Office Box 4000                    )
Princeton, NJ 08543                     )
Attention: Director of Real Estate      )

_______________________________________________________________________________
                                                (Space above for Recorder's use)

     THIS LEASE ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement") is made
as of March 1, 2003 (the "Effective Date"), by and between DELTAGEN RESEARCH
LABORATORIES, LLC, a Delaware limited liability company, f/k/a BMSPRL, L.L.C., a
Delaware limited liability company, successor by conversion pursuant to Section
266 of the Delaware General Corporation Law to Bristol-Myers Squibb Pharma
Research Labs, Inc., a Delaware corporation, f/k/a Dupont Pharmaceuticals
Research Laboratories, Inc., a Delaware corporation, f/k/a CombiChem, Inc., a
Delaware corporation, with an address in care of Deltagen, Inc., 740 Bay Road,
Redwood City, CA 94063-2469, Attention: General Counsel (hereinafter referred to
as "Assignor"), and BRISTOL-MYERS SQUIBB PHARMA COMPANY, a Delaware general
partnership with an address at Post Office Box 4000, Princeton, NJ 08543,
Attention: Director of Real Estate (hereinafter referred to as "Assignee").

                                Recitals of Fact

     A. Assignor is the tenant under that certain Lease between Assignor, as
tenant, and LMC-Executive Investment Company, LLC, a California limited
liability company, as successor to both LMC-Shoreham Investment Company, LLC and
Convoy Court Investment Company, LLC, both California limited liability
companies, as tenants-in-common (hereinafter "Landlord"), as landlord, dated as
of February 23, 1999, as supplemented by that certain Commencement Date
Confirmation establishing the Commencement Date thereunder as January 24, 2000
and that certain Guaranty of Bristol-Myers Squibb Pharma Company (f/k/a Dupont
Pharmaceuticals Company) effective on January 24, 2000 (hereinafter, the
"Lease"), a memorandum of which is intended to be recorded in the Official
Records of the San Diego County Recorder's Office in San Diego, California
concurrently with the execution of this Agreement.

     B. The Lease affects certain premises more particularly described in
Exhibit A to the Lease, which premises comprise a portion of the buildings and
improvements located on the land described on Exhibit A to this Agreement (the
premises which are the subject of the Lease are hereinafter collectively called
the "Premises"; the real property of which the Premises are a part is
hereinafter collectively called the "Property").

<PAGE>

                                                                               2

     C. Assignor desires to assign to Assignee and Assignee desires to accept an
assignment from Assignor of, and to assume the obligations of tenant with
respect to, the leasehold interest and other rights created under the Lease,
effective as of the date of this Agreement.

                                    Agreement

     IN CONSIDERATION of the mutual covenants contained herein, the parties
agree as follows:

     1. Assignment. Assignor does hereby sell, assign, transfer and set over
unto Assignee all of Assignor's right, title and interest to (a) the Lease; (b)
the Premises, (c) any other portion of the Property in which Assignor has any
right or interest under the Lease; (d) the $191,250 Security Deposit made by the
tenant under the Lease, (e) any and all furnishings, fixtures, equipment and
other tangible personal property owned by Assignor and located at the Premises
and (f) all incidental and appurtenant rights which Assignor may have or possess
under or in connection with the Lease, the Premises or the Property. The
conveyance of the property in clause (e) above is made on an "as-is" basis,
without representation, warranty or recourse.

     2. Acceptance and Assumption. Assignee, for itself, its successors and
assigns, hereby accepts said assignment and assumes and agrees to pay and
perform all of the obligations imposed upon Assignor under the terms and
conditions contained in the Lease and agrees to be bound by and to perform,
fulfill and carry out all of the conditions, agreements and provisions to be
performed, fulfilled and carried out by the tenant under said Lease as if
Assignee were the original tenant named thereunder.

     3. Payment of Outstanding February 2003 Rent and other Charges. Assignee
acknowledges and agrees that as of the Effective Date $296,422.61 of the rent
and other charges (the "Outstanding Amount") due to Landlord under the Lease on
February 1, 2003 have not been paid to Landlord. Assignee agrees to pay the
Outstanding Amount and any applicable late fees or charges thereon to Landlord
prior to or concurrently with the mutual execution and delivery of this
Agreement by Assignee and Assignor and the execution and delivery by the
Landlord of the consent of the Landlord annexed hereto.

     4. Miscellaneous. This Agreement shall be governed by the laws of the State
of California and may not be amended except by a document signed by all parties
hereto.

     5. Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed an
original and all of which when taken together shall constitute but one and the
same instrument.

<PAGE>

                                                                               3

         IN WITNESS WHEREOF, the parties hereto have executed this Assignment as
of the date and year first above written.

                                           ASSIGNEE:

                                           BRISTOL-MYERS SQUIBB PHARMA
                                           COMPANY

                                           By: _________________________
                                               Name:
                                               Title:

                                           ASSIGNOR:

                                           DELTAGEN RESEARCH
                                           LABORATORIES, LLC

                                           By: _________________________
                                               Name:
                                               Title:

<PAGE>

                                                                               4

                                Landlord Consent

     LMC-EXECUTIVE INVESTMENT COMPANY, LLC, a California limited liability
company, as successor to both LMC-Shoreham Investment Company, LLC and Convoy
Court Investment Company, LLC, both California limited liability companies, as
tenants-in-common ("Landlord"), through its authorized representative, hereby
consents to the assignment by DELTAGEN RESEARCH LABORATORIES, LLC, a Delaware
limited liability company, f/k/a BMSPRL, L.L.C., a Delaware limited liability
company, as successor by conversion pursuant to Section 266 of the Delaware
General Corporation Law to Bristol-Myers Squibb Pharma Research Labs, Inc., a
Delaware corporation, f/k/a Dupont Pharmaceuticals Research Laboratories, Inc.,
a Delaware corporation, f/k/a CombiChem, Inc., a Delaware corporation (the
"Assignor") of its interest as tenant under that certain lease dated February
23, 1999 (the "Lease") between Assignor and Landlord to BRISTOL-MYERS SQUIBB
PHARMA COMPANY, a Delaware general partnership formerly known as Dupont
Pharmaceuticals Company ("BMS Pharma"), in accordance with the terms of the
attached Lease Assignment and Assumption Agreement (the "Assignment") and the
Lease. Landlord confirms that as of the Effective Date of the Assignment, it is
the landlord under the Lease, the Lease has not been amended or modified, the
Landlord is holding a security deposit in the amount of $191,250 under the
Lease, the Lease is in full force and effect and, to the best knowledge of the
Landlord, except for (i) the failure of tenant to pay $296,422.61 of the rent
and other charges due under the Lease on February 1, 2003 and (ii) ongoing
discussions between the landlord and the tenant with respect to approximately
$250,000 in accrued utility charges, the tenant is not in default thereunder.
The next installment of rent and other charges payable under the Lease is due on
March 1, 2003, the Effective Date.

                                        LMC-EXECUTIVE INVESTMENT COMPANY, LLC

                                        By:_________________________
                                            Name:
                                            Title:

<PAGE>

                                                                               5

                                                    STATE OF NEW YORK   )
                                                                        )
                                                    COUNTY OF NEW YORK  )

     On __________________, before me, _________________, Notary Public,
personally appeared ___________________________, personally known to me (or
proved to me on the basis of satisfactory evidence) to be the person(s) whose
name(s) is/are subscribed to the within instrument and acknowledged to me that
he/she/they executed the same in his/her/their authorized capacity(ies), and
that by his/her/their signature(s) on the instrument the person(s), or the
entity upon behalf of which the person(s) acted, executed the instrument.

     WITNESS my hand and official seal.

     ________________________________________     [SEAL]

STATE OF CALIFORNIA )
                    )
COUNTY OF           )

     On ____________________, before me, _________________________, Notary
Public, personally appeared _____________________, personally known to me (or
proved to me on the basis of satisfactory evidence) to be the person(s) whose
name(s) is/are subscribed to the within instrument and acknowledged to me that
he/she/they executed the same in his/her/their authorized capacity(ies), and
that by his/her/their signature(s) on the instrument the person(s), or the
entity upon behalf of which the person(s) acted, executed the instrument.

     WITNESS my hand and official seal.

     ________________________________________     [SEAL]

<PAGE>

                                                                               6

STATE OF CALIFORNIA )
                    )
COUNTY OF SAN DIEGO )

     On _________________________, before me, _______________________, Notary
Public, personally appeared ___________________________, personally known to me
(or proved to me on the basis of satisfactory evidence) to be the person(s)
whose name(s) is/are subscribed to the within instrument and acknowledged to me
that he/she/they executed the same in his/her/their authorized capacity(ies),
and that by his/her/their signature(s) on the instrument the person(s), or the
entity upon behalf of which the person(s) acted, executed the instrument.

     WITNESS my hand and official seal.

     ________________________________________     [SEAL]

<PAGE>

                                                                               7

                                                                       Exhibit A

                          Legal description of the Land
                              affected by the Lease

          Lot 2 of Nexus Technology Centre Unit No. 1, in the City of San Diego,
          County of San Diego, State of California, according to Map thereof No.
          11876, filed in the Office of the County Recorder of San Diego County,
          August 7, 1987.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]